QRICH1 and cardiac hypertrophy: Looking forward, advancements in CRISPR technology with spatiotemporal editing capabilities, as well as high-throughput screening of chemical libraries to identify small molecule inhibitors that specifically bind and inhibit QRICH1 activity, present promising avenues for targeting QRICH1 in the treatment of myocardial hypertrophy (Akoumianakis et al. 2022; Jackson et al. 2022; Reid et al. 2016).